Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Allison Naleway and Nicola Klein.
Allison Naleway
Connection Strength
8.527
Nicola Klein
  1. Vaccination During Pregnancy in the Vaccine Safety Datalink, 2002-2022. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S105-S107.
    View in: PubMed
    Score: 0.241
  2. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.232
  3. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
    View in: PubMed
    Score: 0.223
  4. Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023. J Infect Dis. 2023 Dec 02.
    View in: PubMed
    Score: 0.222
  5. Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2023 09 01; 142(3):636-639.
    View in: PubMed
    Score: 0.217
  6. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
    View in: PubMed
    Score: 0.214
  7. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.213
  8. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. J Infect Dis. 2023 Jan 23.
    View in: PubMed
    Score: 0.209
  9. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.203
  10. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.201
  11. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.197
  12. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Sep 08.
    View in: PubMed
    Score: 0.190
  13. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
    View in: PubMed
    Score: 0.190
  14. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021; 12:20420986211021233.
    View in: PubMed
    Score: 0.187
  15. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021 06 16; 39(27):3614-3620.
    View in: PubMed
    Score: 0.186
  16. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019 10 16; 37(44):6648-6655.
    View in: PubMed
    Score: 0.166
  17. Reply to Skowronski, De Serres and Orenstein. Clin Infect Dis. 2019 Feb 07.
    View in: PubMed
    Score: 0.159
  18. Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. JMIR Res Protoc. 2019 Jan 21; 8(1):e11333.
    View in: PubMed
    Score: 0.158
  19. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018 10 01; 36(41):6111-6116.
    View in: PubMed
    Score: 0.154
  20. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines. Vaccine. 2017 03 14; 35(12):1615-1621.
    View in: PubMed
    Score: 0.139
  21. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.134
  22. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
    View in: PubMed
    Score: 0.127
  23. Influenza Vaccination During Pregnancy: Influenza Seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2016 Apr; 50(4):480-488.
    View in: PubMed
    Score: 0.127
  24. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
    View in: PubMed
    Score: 0.120
  25. Vaccinations given during pregnancy, 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb; 46(2):150-7.
    View in: PubMed
    Score: 0.112
  26. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013 Dec; 167(12):1111-7.
    View in: PubMed
    Score: 0.111
  27. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May; 129(5):809-14.
    View in: PubMed
    Score: 0.099
  28. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul; 126(1):e1-8.
    View in: PubMed
    Score: 0.087
  29. Patterns in prescribing and dispensing of influenza antivirals among adults with influenza presenting to urgent care and emergency department settings, VISION Network, 2023-2024. Clin Infect Dis. 2025 Apr 04.
    View in: PubMed
    Score: 0.061
  30. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.060
  31. Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. Clin Infect Dis. 2024 Dec 04.
    View in: PubMed
    Score: 0.059
  32. JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States. Infection. 2024 Nov 20.
    View in: PubMed
    Score: 0.059
  33. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.059
  34. Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023. Open Forum Infect Dis. 2024 Sep; 11(9):ofae481.
    View in: PubMed
    Score: 0.058
  35. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.057
  36. Influenza vaccination accuracy among adults: Self-report compared with electronic health record data. Vaccine. 2024 Apr 19; 42(11):2740-2746.
    View in: PubMed
    Score: 0.057
  37. Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders. Influenza Other Respir Viruses. 2024 Mar; 18(3):e13269.
    View in: PubMed
    Score: 0.056
  38. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.056
  39. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023 Dec 12; 41(51):7581-7586.
    View in: PubMed
    Score: 0.055
  40. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season, VISION Network. Clin Infect Dis. 2023 Nov 16.
    View in: PubMed
    Score: 0.055
  41. Effectiveness of the Original Monovalent Coronavirus Disease 2019 Vaccines in Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Adults With Disabilities: VISION Network, June 2021-September 2022. Open Forum Infect Dis. 2023 Nov; 10(11):ofad474.
    View in: PubMed
    Score: 0.055
  42. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 States, June 2021-March 2023. Clin Infect Dis. 2023 Aug 26.
    View in: PubMed
    Score: 0.054
  43. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
    View in: PubMed
    Score: 0.054
  44. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. Am J Transplant. 2023 07; 23(7):1062-1076.
    View in: PubMed
    Score: 0.054
  45. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.054
  46. Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. Vaccine. 2023 05 22; 41(22):3429-3435.
    View in: PubMed
    Score: 0.053
  47. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.053
  48. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.053
  49. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. Am J Epidemiol. 2023 Feb 01; 192(2):205-216.
    View in: PubMed
    Score: 0.052
  50. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.052
  51. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.052
  52. Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022. J Infect Dis. 2022 Nov 23.
    View in: PubMed
    Score: 0.052
  53. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.051
  54. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.051
  55. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.050
  56. Influenza Vaccination Among Pregnant Women: Self-report Compared With Vaccination Data From Electronic Health Records, 2018-2020 Influenza Seasons. Public Health Rep. 2022 Jun 08; 333549221099932.
    View in: PubMed
    Score: 0.050
  57. Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
    View in: PubMed
    Score: 0.050
  58. Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015-2017. J Low Genit Tract Dis. 2022 Apr 01; 26(2):135-139.
    View in: PubMed
    Score: 0.049
  59. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.049
  60. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.049
  61. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.049
  62. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.049
  63. A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010-2016. Vaccine. 2021 12 20; 39(52):7598-7605.
    View in: PubMed
    Score: 0.048
  64. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.048
  65. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.048
  66. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.048
  67. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.047
  68. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open. 2021 04 01; 4(4):e214340.
    View in: PubMed
    Score: 0.046
  69. Developing algorithms for identifying major structural birth defects using automated electronic health data. Pharmacoepidemiol Drug Saf. 2021 02; 30(2):266-274.
    View in: PubMed
    Score: 0.045
  70. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
    View in: PubMed
    Score: 0.045
  71. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
    View in: PubMed
    Score: 0.044
  72. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics. 2010 Aug; 126(2):263-9.
    View in: PubMed
    Score: 0.044
  73. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine. 2020 08 18; 38(37):5880-5884.
    View in: PubMed
    Score: 0.043
  74. Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016. J Infect Dis. 2020 04 27; 221(10):1703-1712.
    View in: PubMed
    Score: 0.043
  75. Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. J Infect Dis. 2020 03 02; 221(6):910-918.
    View in: PubMed
    Score: 0.043
  76. Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season. Vaccine. 2020 02 24; 38(9):2202-2208.
    View in: PubMed
    Score: 0.042
  77. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010 Jan; 29(1):1-5.
    View in: PubMed
    Score: 0.042
  78. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.042
  79. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019 10 16; 37(44):6673-6681.
    View in: PubMed
    Score: 0.041
  80. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.041
  81. Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
    View in: PubMed
    Score: 0.040
  82. Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010-2016. Clin Infect Dis. 2018 Nov 28; 67(12):1915-1918.
    View in: PubMed
    Score: 0.039
  83. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine. 2019 Jan 03; 37(1):76-79.
    View in: PubMed
    Score: 0.039
  84. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010-2016. Clin Infect Dis. 2018 Oct 11.
    View in: PubMed
    Score: 0.039
  85. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. Obstet Gynecol. 2018 Jul; 132(1):35-44.
    View in: PubMed
    Score: 0.038
  86. Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics. 2018 03; 141(3).
    View in: PubMed
    Score: 0.037
  87. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.037
  88. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf. 2018 Jan; 27(1):59-68.
    View in: PubMed
    Score: 0.036
  89. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine. 2017 09 25; 35(40):5314-5322.
    View in: PubMed
    Score: 0.036
  90. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine. 2017 10 13; 35(43):5872-5877.
    View in: PubMed
    Score: 0.036
  91. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
    View in: PubMed
    Score: 0.036
  92. Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. Pediatr Neurol. 2017 Nov; 76:72-78.
    View in: PubMed
    Score: 0.036
  93. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.035
  94. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. J Pediatr. 2017 08; 187:234-239.e4.
    View in: PubMed
    Score: 0.035
  95. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.034
  96. Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies. Am J Epidemiol. 2016 08 01; 184(3):176-86.
    View in: PubMed
    Score: 0.033
  97. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics. 2016 07; 138(1).
    View in: PubMed
    Score: 0.033
  98. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016 Feb 10; 34(7):968-73.
    View in: PubMed
    Score: 0.032
  99. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol. 2015 Nov; 126(5):1069-74.
    View in: PubMed
    Score: 0.032
  100. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015 Oct 20; 314(15):1581-7.
    View in: PubMed
    Score: 0.032
  101. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12; 312(18):1897-904.
    View in: PubMed
    Score: 0.030
  102. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
    View in: PubMed
    Score: 0.030
  103. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014 Sep 22; 32(42):5390-8.
    View in: PubMed
    Score: 0.029
  104. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
    View in: PubMed
    Score: 0.029
  105. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014 Jun; 133(6):e1492-9.
    View in: PubMed
    Score: 0.029
  106. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014 Feb 06; 370(6):513-9.
    View in: PubMed
    Score: 0.028
  107. Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
    View in: PubMed
    Score: 0.026
  108. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
    View in: PubMed
    Score: 0.026
  109. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.024
  110. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
    View in: PubMed
    Score: 0.024
  111. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011 May; 127 Suppl 1:S45-53.
    View in: PubMed
    Score: 0.023
  112. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.023
  113. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.021
  114. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
    View in: PubMed
    Score: 0.020

© 2025 Kaiser Permanente

Your Privacy Choices